1 |
Dispenzieri A, Armitage JO, Loe MJ, Geyer SM, Allred J, Camoriano JK, et al. The clinical spectrum of Castleman's disease. Am J Hematol 2012;87:997-1002.
DOI
|
2 |
Day JR, Bew D, Ali M, Dina R, Smith PL. Castleman's disease associated with myasthenia gravis. Ann Thorac Surg 2003;75:1648-1650.
DOI
|
3 |
Chorzelski T, Hashimoto T, Maciejewska B, Amagai M, Anhalt GJ, Jablonska S. Paraneoplastic pemphigus associated with Castleman tumor, myasthenia gravis and bronchiolitis obliterans. J Am Acad Dermatol 1999;41:393-400.
DOI
|
4 |
Wang HW, Pittaluga S, Jaffe ES. Multicentric Castleman disease: where are we now? Semin Diagn Pathol 2016;33:294-306.
DOI
|
5 |
Cheuk W, Chan JK. Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity. Semin Diagn Pathol 2012;29:226-234.
DOI
|
6 |
Hurst RL, Gooch CL. Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis. Curr Neurol Neurosci Rep 2016;16:61.
DOI
|
7 |
Oh SJ. Muscle-Specific receptor tyrosine kinase antibody positive myasthenia gravis current status. J Clin Neurol 2009;5:53-64.
DOI
|
8 |
Sylvester J, Purdie G, Slee M, Gray JX, Burnet S, Koblar S. Muscle-specific kinase antibody positive myaesthenia gravis and multiple sclerosis co-presentation: a case report and literature review. J Neuroimmunol 2013;264:130-133.
DOI
|